Voluntis

Voluntis develops innovative digital therapeutics that enhance patient treatment experiences through personalized, algorithm-driven solutions, improving healthcare outcomes for patients and their care teams. Founded in 2001 in Suresnes, France, Voluntis specializes in digital therapeutics, focusing on enhancing patient treatment experiences. The company has undergone no notable pivots in its business strategy. CEO and founder Pierre Leurent has a history of leading healthcare technology innovations.

Voluntis has secured a total of EUR 10. 375 mn in funding across several rounds, with the latest being a Series C round led by Bpifrance Investissement on September 2, 2021, bringing its total amount raised to EUR 10. 375 mn and current valuation to EUR 30. 515 mn.

Voluntis specializes in developing digital therapeutics (DTx) that enhance treatment experiences by providing personalized, algorithm-driven solutions for patients and care teams. The core product, the Theraxium platform, effectively creates digitally-augmented therapies tailored to user needs, integrating evidence-based clinical algorithms for automated patient recommendations. This platform has achieved regulatory clearances in the United States, Canada, and Europe, focusing on oncology and chronic diseases. Voluntis collaborates with pharmaceutical partners to enhance complex health conditions and improve patient engagement through actionable insights.

For the most recent year, 2023, Voluntis reported a revenue of EUR 7,471,077. 20 with an EBITDA of EUR -4,504,407. 40, primarily generated through collaboration agreements with pharmaceutical companies that utilize its DTx offerings for enhancing their therapeutic products. Voluntis plans to expand its product line further into new digital therapeutics tailored for specific therapeutic areas while enhancing its Theraxium platform.

The company targets growth in new geographic markets, looking into expansion opportunities in North America and Europe by the end of 2023. The recent Series C funding of EUR 10. 375 mn will support these initiatives, particularly focusing on enhancing product development and market penetration. In September 2022, AptarGroup, Inc.

acquired 64. 6% of Voluntis’s share capital, with further plans for a mandatory cash tender offer for the remaining shares, indicating a commitment to long-term growth and innovation.